US FDA Approved Lung Cancer Drug by Mirati Therapeutics

The US Food and Drug Administration (FDA) has approved KRAZATI, a targeted treatment for adult patients with KRAS metastatic non-small cell lung cancer (NSCLC), developed by Mirati Therapeutics Inc. Based on the objective response rate (ORR) and duration of response (DOR), the treatment receives expedited approval. The description and verification of a clinical benefit in […]

Continue Reading

scPharmacueticals’ Heart Failure Therapy Approved by US FDA

The US Food and Drug Administration (FDA) of the United States has approved the on-body infusor ‘Furoscix’ for congestive heart failure developed by scpharmaceuticals. With this approval, Furoscix becomes the first self-administered, and subcutaneous loop diuretic for people with worsening heart failure. This infusor delivers generic furosemide that relieves fluid retention and swelling, which causes […]

Continue Reading